Author

M. Escorihuela

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 3 Approach:experimental assay· 3 Organism:human· 3 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Organism:mouse· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

J. Arribas· 3 shared A. García de Herreros· 1 shared A. Grinyo-Escuer· 1 shared A. Millanes-Romero· 1 shared B. Morancho· 1 shared C. Jerónimo· 1 shared C. Klein· 1 shared C. S.-O. Attolini· 1 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

J. Arribas

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

The efficacy of chemotherapy is limited by intratumoural senescent cells that persist through the upregulation of PD-L2

S. Chaib, J. A. Lopez-Dominguez, M. Lalinde, N. Prats, I. Marin, K. Meyer, M. I. Munoz, M. Aguilera, L. Mateo, C. S.-O. Attolini, S. Llanos, M. Escorihuela, S. Perez-Ramos, F. Al-Shahrour, T. P. Cash, , M. Serrano

This study identifies PD-L2 as a marker of therapy-induced senescent cells that suppress chemotherapy efficacy, showing PD-L2 blockade enhances tumour remission in mice.

bioRxiv · Nov 4, 2022 · PreprintCancer Biology

Humanized CAR T cells targeting p95HER2

M. Roman, I. Rius Ruiz, A. Grinyo-Escuer, S. Duro-Sanchez, M. Escorihuela, E. Moessner, C. Klein, J. Arribas

This study develops CAR T cells targeting p95HER2, a tumor-specific antigen, showing efficacy against HER2-amplified tumors and metastases with reduced off-tumor effects.

bioRxiv · May 20, 2022 · PreprintCancer Biology

Maintaining oxidized H3 in heterochromatin is required for the oncogenic capacity of triple-negative breast cancer cells

G. Serra-Bardenys, T. V. Tian, E. Blanco, J. Querol, L. Pascual-Reguant, B. Morancho, M. Escorihuela, S. Segura-Bayona, G. Verde, R. Aiese Cigliano, A. Millanes-Romero, C. Jerónimo, P. Nuciforo, S. Simonetti, C. Viaplana, , S. Peiró

This study identifies the role of H3K4ox in maintaining heterochromatin structure in TNBC cells and shows its necessity for oncogenic properties.

bioRxiv · Jan 30, 2020 · PreprintCancer Biology